Recce Pharmaceuticals

Recce Pharmaceuticals Operating Expenses

The Total Operating Expenses of Recce Pharmaceuticals (RCE.AX) as of Nov 22, 2026 is 8.68 M AUD. In the previous year, Total Operating Expenses was 18.70 M AUD — a change of -53.60% (lower).

Operating Expenses

8.68 MAUD

YoY

-53.60%

Last updated:

Total Operating Expenses of Recce Pharmaceuticals is 2026 8.68 M AUD. Total Operating Expenses of Recce Pharmaceuticals was 2025 18.70 M AUD. It decreases by -53.60% lower compared to the previous year.

The Recce Pharmaceuticals Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
2.01 M AUD
Jan 1, 2020
3.73 M AUD
Jan 1, 2021
12.37 M AUD
Jan 1, 2022
8.60 M AUD
Jan 1, 2023
11.28 M AUD
Jan 1, 2024
12.91 M AUD
Jan 1, 2025
18.70 M AUD
Jan 1, 2026
8.68 M AUD
The Recce Pharmaceuticals Operating Expenses history
YEAROperating ExpensesYoY
8.68 MAUD-53.60%
18.70 MAUD+44.86%
12.91 MAUD+14.48%
11.28 MAUD+31.21%
8.60 MAUD-30.51%
12.37 MAUD+231.32%
3.73 MAUD+85.51%
2.01 MAUD+17.77%
1.71 MAUD-32.70%
2.54 MAUD-41.35%
4.33 MAUD+612.87%
607,350.00AUD+157.72%
235,660.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Total Operating Expenses of Recce Pharmaceuticals is 8.68 M AUD in 2026.

Total Operating Expenses of Recce Pharmaceuticals changed from 18.70 M AUD to 8.68 M AUD, representing a -53.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Recce Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Recce Pharmaceuticals

All Key Metrics — Recce Pharmaceuticals